Chinese Expert Consensus on the Clinical Application of Low Molecular Weight Heparins

Thromboembolic diseases represent a leading global disease burden. Low molecular weight heparins(LMWHs), as anticoagulants, play a critical role in the prevention and treatment of these conditions. However, there are numerous instances of irrational use of LMWHs in clinical practice. To address this issue, the Precision Pharmacology Committee of the Chinese Pharmacists Association convened multidisciplinary experts to develop this consensus. Based on the latest domestic and international evidence, and utilizing the GRADE methodology, this consensus was developed to standardize the rational use of LMWHs. The consensus comprehensively addresses the pharmacological properties of LMWHs, clinical applications, management of adverse reactions, drug interactions, and pharmaceutical care, providing clinicians, pharmacists, and related healthcare professionals with evidence-based guidance. It has identified 14 clinical issues and formed 37 recommendations. This initiative aims to promote standardized application of LMWHs, ensure medication safety, and improve clinical outcomes.